Good start to 2013 for Stada Arz in German tender process
German drugmaker Stada Arzneimittel’s (SAZ: GR) sales companies- STADApharm and ALIUD Pharma - have also successfully begun 2013 in the tender process for discount agreements: they won awards for a total of 84 active pharmaceutical ingredients and active ingredient combinations with the three largest public health insurance organizations and associations in Germany.
The only independent German generics group thereby provides its medicines to over 40 million insured persons of the Allgemeine Ortskrankenkasse (AOK), Barmer GEK and Techniker Krankenkasse (TK). The medicines include frequently needed active ingredients such as omeprazole.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze